Synthetic Biology: Emerging Global Markets
The global value of the synthetic biology market reached $1.1 billion in 2010. It is expected to reach $1.6 billion in 2011 and it will further grow to $10.8 billion by 2016, increasing at a compound annual growth rate (CAGR) of 45.8.%.
The study’s scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercial or forecast to be commercialized within the next 5 years.
We analyze key synthetic biology technologies and products to determine present and future market status, and forecast growth from 2011 through 2016. We also discuss strategic alliances, industry structures, competitive dynamics, patent strategy, and market driving forces.
BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and specialty chemicals. The role of key strategic alliances from 2009 through 2011 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, and chassis organisms are analyzed, as well as metabolically-engineered factories for producing synthetic fuels and specialty chemicals. The main companies in these fields are highlighted.
John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.
- The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%.
- The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%.
- The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013.